MAIA Biotechnology, Inc. (MAIA)

NYSEAMERICAN: MAIA · Real-Time Price · USD

1.250

+0.010 (0.81%)

Apr 28, 2026, 4:00 PM EDT - Market closed

MAIA Biotechnology Employees

MAIA Biotechnology had 13 employees as of December 31, 2025. The number of employees did not change compared to the previous year.

Employees

13

Change (1Y)

n/a

Growth (1Y)

n/a

Revenue / Employee

n/a

Profits / Employee

-$1,722,782

Market Cap

75.84M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2025	13	0	-
Dec 31, 2024	13	0	-
Dec 31, 2023	13	-5	-27.78%
Dec 31, 2022	18	9	100.00%
Dec 31, 2021	9	-	-

Related Stocks

Company Name	Employees
TScan Therapeutics	142
Pelthos Therapeutics	92
XBiotech	85
ImmuCell	73
Seres Therapeutics	66
aTyr Pharma	60
PMV Pharmaceuticals	54
Pliant Therapeutics	49

Employee Rankings

MAIA News

20 days ago - MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy - GlobeNewsWire
4 weeks ago - MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer - GlobeNewsWire
4 weeks ago - Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - GlobeNewsWire
7 weeks ago - MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock - GlobeNewsWire
2 months ago - MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
2 months ago - MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market - GlobeNewsWire
3 months ago - MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum - GlobeNewsWire
4 months ago - MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings - GlobeNewsWire